Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P08195

UPID:
4F2_HUMAN

ALTERNATIVE NAMES:
4F2 cell-surface antigen heavy chain; 4F2 heavy chain antigen; Lymphocyte activation antigen 4F2 large subunit; Solute carrier family 3 member 2

ALTERNATIVE UPACC:
P08195; J3KPF3; Q13543

BACKGROUND:
SLC3A2, a key player in amino acid transport, partners with SLC7 family members to form heterodimers essential for amino acid exchange. Its involvement in transporting a wide range of amino acids, including dibasic and neutral amino acids, underscores its significance in cellular metabolism. Additionally, SLC3A2's role in facilitating hepatitis C virus entry and mTORC1 signaling activation through L-leucine uptake highlights its potential in viral pathogenesis.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifunctional nature of SLC3A2 offers a promising avenue for developing novel therapeutic interventions, particularly in combating diseases associated with viral entry and amino acid transport dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.